Score Overview
Explore the 2021 public Archive ranking →
Where Chemomab Therapeutics Ltd DRC has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CMMB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-13 | $ 1.24 | — |
1 Year2025-10-13 | $ 3.36 | -63.10% |
5 Years2021-10-13 | $ 37.64 | -96.71% |
All Time2019-02-12 | $ 691.20 | -99.82% |
| Period | Last Price2026-10-13 | 1 Year2025-10-13 | 5 Years2021-10-13 | All Time2019-02-12 |
|---|---|---|---|---|
| Price | $ 1.24 | $ 3.36 | $ 37.64 | $ 691.20 |
| Return | — | -63.10% | -96.71% | -99.82% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 7M | $ 6M |
| 2025 | $ 0.00 | -$ 8M | $ 10M |
| 2024 | $ 0.00 | -$ 13M | $ 14M |
| 2023 | $ 0.00 | -$ 24M | $ 19M |
| 2022 | $ 0.00 | -$ 27M | $ 39M |
| 2021 | $ 0.00 | -$ 12M | $ 61M |
| 2020 | $ 0.00 | -$ 11M | $ 11M |
| IPO2019 | $ 0.00 | $ 27M | $ 17M |
Chemomab Therapeutics Ltd DRC fundamental performance
Across Chemomab Therapeutics Ltd DRC's full reported history, from 2019 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from $ 27M to -$ 8M. Revenue increased in 0% of the years measured; net income in 57%.
Membership
Explore CMMB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,125 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
